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Objective. The RET proto-oncogene is known to be
the susceptibility gene for various disease pheno-
types, including multiple endocrine neoplasia type 2
(MEN 2). Recent studies have also suggested an
involvement of RET in the development of the
mammalian kidney. Although kidney agenesis or
dysgenesis has been observed in mice lacking
functional ret, no clinically relevant kidney abnor-
malities have been reported in individuals with
known RET mutations and familial medullary thy-
roid carcinoma (FMTC). We have studied a family
with five members affected with isolated FMTC. DNA
analysis was performed and the involved RET
mutation was identified. Amongst these patients
were a woman and her son.
Design. Case report.
Setting. University department.
Patients. A 32-year-old woman and her son with
FMTC and unilateral renal agenesis.
Results. The woman’s abdominal ultrasound find-
ings demonstrated unilateral renal absence of the
left kidney. Her son, when only a few months old,
had undergone surgical treatment for Hirsch-
sprung’s disease. Abdominal ultrasonography was
performed recently, and left-side renal absence was
diagnosed. Intravenous pyelography confirmed the
agenesis of his left kidney, whilst the contralateral
kidney displayed compensatory hypertrophy.
Conclusions. The involvement of the RET proto-
oncogene in the early growth and differentiation of
the human kidney is now generally accepted. We
believe that at least a proportion of patients with
MEN 2 may have undiagnosed renal malformations.
We suggest therefore that noninvasive imaging
techniques, such as ultrasonography, should be
used to explore the presence of renal abnormalities
in subjects with demonstrated RET mutations.
Keywords: FMTC, germline mutations, Hirsch-
sprung disease, kidney, MEN 2, RET proto-oncogene,
thyroid neoplasms, urogenital abnormalities.
Introduction
Medullary thyroid carcinoma (MTC), a tumour of
the parafollicular C cells of the thyroid, may occur in
two presentations: a sporadic form, which accounts
for the majority of cases, and a familial counterpart
arising as the major component of an autosomal
dominantly inherited cancer syndrome, multiple
endocrine neoplasia type 2 (MEN 2) [1].
Depending on the tissues involved, MEN 2 is
divided into three variants: MEN 2A (involving
families with MTC, pheochromocytoma and, less
commonly, hyperparathyroidism), MEN 2B (invol-
ving families with MTC, with or without pheo-
chromocytoma and with characteristic clinical
abnormalities, such as ganglioneuromas of the lips,
tongue and colon, but without hyperparathyroidism)
and familial medullary thyroid carcinoma (FMTC).
Familial medullary thyroid carcinoma is clinically
defined by the presence of MTC in a minimum of
four family members, with no objective evidence of
pheochromocytoma or parathyroid involvement on
screening of all living affected and at-risk subjects
[2, 3].
Germline mutations in the RET proto-oncogene,
which encodes a cell-surface glycoprotein related to
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the family of receptor tyrosine kinases [4], have been
identified in over 90% of families with MEN 2 [5].
Mutations of the RET gene are also the underlying
genetic cause in a proportion of patients with
Hirschsprung’s disease, a congenital absence of
innervation in the lower intestinal tract. In a very
small fraction of kindreds, MEN 2 cosegregates with
Hirschsprung’s disease [6].
Recent studies have suggested that the RET proto-
oncogene may also play an essential role in renal
morphogenesis. It has been demonstrated that ret
knockout mice (ret–/–) display kidney agenesis or
severe kidney dysgenesis [7]. Moreover, one of the
ligands for RET, the glial cell line-derived neuro-
trophic factor (GDNF), has also been shown to be
essential for kidney development [8, 9]. However, no
renal abnormalities have been reported amongst
patients with known RET mutations in association
with MTC.
We describe a family with FMTC and Hirsch-
sprung’s disease, in association with a known RET
mutation, in which two members exhibit unilateral
kidney agenesis [10].
Case report
The pedigree of the family is shown in Fig. 1. A
56-year-old woman (patient III-1), in whom MTC
had been diagnosed at the age of 42 years, following
a total thyroidectomy performed because of a
suspect thyroid nodule, was referred to the Endo-
crinology Unit of our hospital for evaluation of a
neck mass. She was shown to have high serum
calcitonin levels and the diagnosis of lymph node
metastasis of MTC was confirmed histologically.
Almost simultaneously, the 44-year-old brother of
patient III-1 (patient III-2) underwent thyroidecto-
my in the surgical department of the same hospital
and was diagnosed as having MTC. Following
surgery, he was also referred to our department.
Elevated serum calcitonin levels (in the basal
state and following pentagastrin stimulation) and
subsequently available DNA analysis led to the
identification of an additional family member with
MTC (IV-1). Two other subjects at risk (V-2V-4),
were demonstrated to have the same RET proto-
oncogene mutation (C620S) as identified in the
affected members of the family. The results of the
genetic studies have been reported in a separate
paper [11].
Subsequent research into the medical history of
the parents of patients III-1 and III-2 revealed that
the mother (patient II-1) had undergone total
thyroidectomy in 1971 for a thyroid tumour which,
at that time, had been histologically diagnosed as
‘undifferentiated small cell carcinoma’. Recent his-
tological re-examination of the surgical specimen
using calcitonin antibodies led to the diagnosis of
MTC 26 years after surgery.
Altogether, 13 family members were studied. The
C620S RET mutation was detected in five of them,
including subject V-4, who, at the age of 8 years,
had no evidence of MTC.
Medullary thyroid carcinoma was diagnosed in
five patients, including patient II-1, who died of
unknown causes in 1979, at the age of 63. PCR
could not be performed on the tissue sections of this
patient. Screening for MEN 2-associated tumours
included 24-h urinary free catecholamines, urinary
vanillylmandelic acid and serum calcium and para-
thyroid hormone levels in all the living affected and
at-risk subjects.
Patient IV-1
A 32-year-old woman, the daughter of patient III-1,
was one of the relatives contacted during our
investigation. Serum calcitonin levels were found
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Fig. 1 Pedigree of the family. The arrow indicates the patient who
brought the family to our attention (proband). Gray symbols
indicate members with medullary thyroid carcinoma (MTC),
hatched symbols the members with MTC and renal agenesis, and
symbols with a slash deceased family members. The symbol with a
square indicates a member with the C620S RET mutation, but
with no evidence of thyroid tumour at the age of eight. The small
blackened circle represents a miscarriage. The parallel bars
indicate no offspring.
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to be abnormally high, both in the basal state and
following pentagastrin stimulation. Ultrasonogra-
phy revealed two small hypoechoic nodules located
in the right and left thyroid lobes (with a maximum
diameter of 9 and 6 mm, respectively). Fine needle
aspiration biopsy revealed cytological findings sug-
gesting thyroid cancer. The patient underwent total
thyroidectomy with regional lymph node dissection.
Histopathologic examination confirmed the diagno-
sis of MTC.
Abdominal ultrasonography demonstrated unilat-
eral renal absence involving the left kidney. The
Fig. 2 Radionuclide imaging (99mTc methylene bisphosphonate) of patient IV-1: absence of the left kidney and hypertrophic right kidney.
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right kidney was found to be hypertrophic. Radio-
nuclide imaging confirmed these findings (Fig. 2).
Laboratory tests indicated normal renal function.
Patient V-2
The second son of patient IV-1. He had displayed
persistent constipation with abdominal distension
immediately after birth. A barium enema had shown
evidence of long-segment megacolon. Following
surgical resection, histological examination revealed
total aganglionosis and the diagnosis of Hirsch-
sprung’s disease was made. At that time the
presence of MTC amongst family members was not
known.
Subsequently, serum calcitonin levels were found
to be normal, in the basal state as well as following
pentagastrin stimulation. The availability of DNA
analysis made it possible to detect the C620S RET
mutation [11] and the patient underwent prophy-
lactic total thyroidectomy. Histopathologically, MTC
was diagnosed.
Abdominal ultrasonography was recently per-
formed and left-side renal absence diagnosed. Intra-
venous pyelography confirmed agenesis of the left
kidney, whilst the contralateral kidney displayed
compensatory hypertrophy. Renal function was
normal.
No renal abnormalities were found in the other
family members.
Discussion
Germline mutations affecting one of five cysteines
(Cys 609, 611, 618, 620 and 634) located in the
juxtamembrane domain of the RET receptor are
responsible for the vast majority of MEN 2A and
FMTC cases. These mutations lead to the replace-
ment of a cysteine residue by another amino
acid [6].
It has been demonstrated that the oncogenic
potential of RET is a consequence of the constitutive
tyrosine kinase activity conferred by MEN 2 muta-
tions [12, 13], whilst inactivating RET mutations
are believed to be responsible for Hirschsprung’s
disease and renal agenesis [14]. Therefore, the
cosegregation of MEN 2A and Hirschsprung’s dis-
ease in certain families represents a puzzling phe-
nomenon. The molecular basis of this finding has
probably been provided by the experimental work of
Chappuis-Flament et al., who have shown that
mutations at cysteines 609, 618 and 620 may
result in a marked decrease in the plasma membrane
expression of RET protein and, consequently, in the
amount of RET covalent dimer [6]. Thus, unique
mutations at cysteines 609, 618 and 620 may exert
both activating as well as inactivating effects,
depending on the tissue in which RET is expressed.
Additional mutations in tyrosine kinase coreceptor
and/or ligand genes may have a role in this
pathological process [15].
During development, the receptor tyrosine kinase
encoded by the RET proto-oncogene is expressed in a
variety of tissues including the peripheral and
central nervous systems and the kidney [16, 17].
In the latter, factors from the metanephric mesen-
chyme induce the growth and repeated branching of
the ureteric bud, which gives rise to the collecting
duct system and also induces nephrogenesis [18]. It
has been ascertained that the signalling pathways
required for this process include the RET ligand
GDNF, produced in the metanephric mesenchyme,
the receptor tyrosine kinase RET, and the coreceptor
GFRa-1 (GDNF family receptor a one), both of which
are expressed in the ureteric bud [8, 9, 19]. This has
clearly been demonstrated in experimental animals:
both GDNF and ret null mice display severe renal
abnormalities and lack enteric neurones in a pattern
that resembles human Hirschsprung’s disease
[7, 20].
It has recently been shown that RET is also
expressed in the human foetal kidney and its highest
expression coincides with a stage of renal morpho-
genesis in which the ureteric bud undergoes rapid
branching [21]. RET gene expression has also been
found in human enteric neuroblasts of the develop-
ing enteric nervous system [22]. Yet, despite these
findings, only few cases of renal agenesis have been
reported in Hirschsprung’s disease patients [22] and
no case of renal malformation has been described in
patients with FMTC.
In the light of available data regarding the role of
the RET gene in experimental animals and in
humans, the finding of renal agenesis in our two
patients with a C620S mutation cannot be consid-
ered purely coincidental.
We believe that the association we have observed
is not necessarily exceptional. It is possible that renal
abnormalities have not been diagnosed in MEN 2
patients because abdominal imaging is not routinely
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performed in such cases, given that the screening for
pheochromocytoma and hyperparathyroidism in
patients with MTC is generally based on laboratory
tests [23].
Therefore, we suggest that an extensive study
should be performed in order to establish the
actual prevalence of major renal abnormalities in
families with MEN 2 and mutations at cysteines
609, 618 or 620. We also propose that nonin-
vasive and cost-effective diagnostic procedures,
such as ultrasonography, should be routinely
performed, in the setting of the initial clinical
evaluation, in patients with suspected MEN, and
their relatives, in order to detect possible renal
alterations, as renal malformations may have
medical implications even for asymptomatic
patients. Subjects with unilateral renal absence
require lifetime follow-up [24], as hypertension
and various degrees of renal insufficiency have
been reported in long-term studies of patients
with a single kidney [25, 26].
Despite the general expectation that mutations in
a single gene are associated with one distinct
phenotype, recent reports have shown that muta-
tions in the receptor tyrosine kinase gene RET may
lead to four different phenotypes (FMTC, MEN 2A,
MEN 2B and Hirschsprung’s disease) [27]. Our
findings seem to indicate the existence of a fifth
phenotype associated with constitutional mutations
of the RET proto-oncogene.
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